trending Market Intelligence /marketintelligence/en/news-insights/trending/ZOZtN_BpYKc3vzESJay_SQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Intellipharmaceutics shares to start trading on OTCQB Venture Market

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Intellipharmaceutics shares to start trading on OTCQB Venture Market

Intellipharmaceutics International Inc. said its common shares will trade on the OTCQB Venture Market under the IPCI symbol beginning March 21.

Meanwhile, the company's shares will be suspended from trading on Nasdaq effective at the open of business March 21. The suspension was due to noncompliance with the stock market's $1 bid price listing requirement.

The company's trading status on the Toronto Stock Exchange is not affected by its noncompliance with Nasdaq's listing rules, Intellipharmaceutics noted.

Toronto-based Intellipharmaceutics develops and manufactures controlled-release and targeted pharmaceutical products, with a particular focus in the opioid abuse deterrence segment.